| Attributes | Values |
|---|
| rdf:type
| |
| description
| - wetenschappelijk artikel (nl)
- article scientifique publié en 2006 (fr)
- наукова стаття, опублікована в січні 2006 (uk)
- im Jahr 2006 veröffentlichter wissenschaftlicher Artikel (de)
- artículu científicu espublizáu en xineru de 2006 (ast)
- artikull shkencor i botuar më 01 janar 2006 (sq)
- scientific article published on 01 January 2006 (en)
|
| publication date
| |
| publication date
| |
| author name string
| |
| author name string
| - Buddha Basnyat
- Jeffrey H Gertsch
- Peter S Holck
- Ross J Fleischman
- E William Johnson
- Kelly B Philpot
- Jason S Hawksworth
- Benjamin P Donham
- Adam H Loveridge
- Brett T Jensen
- Daniel P Miegs
- Daniel W Gowder
- Elizabeth B Lundeen
- Jesse A Noboa
- Kenneth A O'Beirne
- Mandie R Wiebers
- Matthew C Valente
- Miriam N Schultz
- Richard J Kleiman
- Sheri L Newman
|
| rdfs:label
| - Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial (en)
- Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial (nl)
- Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial (sq)
|
| skos:prefLabel
| - Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial (en)
- Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial (nl)
- Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial (sq)
|
| name
| - Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial (en)
- Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial (nl)
- Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial (sq)
|
| author
| |
| author
| |
| title
| |
| title
| - Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial (en)
|
| page(s)
| |
| page(s)
| |
| instance of
| |
| instance of
| |
| main subject
| |
| main subject
| |
| PubMed ID
| |
| PubMed ID
| |
| PubMed ID
| |
| published in
| |
| published in
| |
| issue
| |
| volume
| |
| issue
| |
| volume
| |
| DOI
| |
| DOI
| |
| DOI
| |
| is about
of | |
| is cites work
of | - Alterations in cerebral blood flow and cerebrovascular reactivity during 14 days at 5050 m.
- Altitude Sickness in Climbers and Efficacy of NSAIDs Trial (ASCENT): randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness
- Acetazolamide pre-treatment before ascending to high altitudes: when to start?
- Cerebral pressure-flow relationship in lowlanders and natives at high altitude
- The cerebral effects of ascent to high altitudes
- Wilderness Medical Society practice guidelines for the prevention and treatment of acute altitude illness: 2014 update.
- Spironolactone Does Not Prevent Acute Mountain Sickness: A Prospective, Double-Blind, Randomized, Placebo-Controlled Trial by SPACE Trial Group (Spironolactone and Acetazolamide Trial in the Prevention of Acute Mountain Sickness Group)
- Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic review and meta-analysis
- Acute high-altitude illness: a clinically orientated review
- Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness
- Conduit artery structure and function in lowlanders and native highlanders: relationships with oxidative stress and role of sympathoexcitation.
- Prospective, double-blind, randomized, placebo-controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT).
- High-altitude illnesses: physiology, risk factors, prevention, and treatment
- Influence of cerebral blood flow on central sleep apnea at high altitude
- Acetazolamide during acute hypoxia improves tissue oxygenation in the human brain
- Rhodiola crenulata extract for prevention of acute mountain sickness: a randomized, double-blind, placebo-controlled, crossover trial
|
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)